Pamela Sklar is a neuroscientist, human geneticist and clinical psychiatrist investigating the genetic causes of psychiatric disorders, including schizophrenia and bipolar disorder. A major focus of her prior work has been to identify susceptibility genes for psychiatric diseases by applying tools developed for understanding and characterizing human sequence variation. Currently, she is Chief of the Division of Psychiatric Genomics, and Professor of Psychiatry, Neuroscience, Genetics and Genomic Sciences.
Depression, Epigenetics, Genetics, Human Genetics and Genetic Disorders, Schizophrenia, Stem Cells, Synapses, Synaptic Plasticity, Synaptogenesis
Genetics and Genomic Sciences [GGS], Neuroscience [NEU]
BA, St. John's College
MD, PhD, Johns Hopkins School of Medicine
Division of Psychiatric Genomics
Using as a foundation the superb basic and clinical resources of the Mount Sinai Medical Center we will build an infrastructure for improving the diagnosis and treatment of psychiatric diseases. The Division of Psychiatric Genetics and Genomics that includes a Laboratory of Psychiatric Genomics, a Laboratory of Molecular Analysis of Risk Genes for Psychiatric Disorders: SCZ (SCZ), Bipolar Disorder (BD), MDD and OCD, and a Laboratory of Translational Psychiatry.
Division and Lab Website
http://research.mssm.edu/psychgenomics/ and http://research.mssm.edu/psychgenomics/sklar-lab/
The laboratory of psychiatric genomics will continue the long-standing basic research program of the PI to define the genetic architecture of the two most severe and heritable adult psychiatric disorders, BD and SCZ. Understanding the architecture requires knowing the number, frequency and effect size (and how they interact) of all the genetic risk factors and these would be undertaken in collaboration with members of the Genomics institute.
Studies are ongoing in the areas of:
1) large scale genome-wide association studies
2) rare variant identification by next generation sequencing
3) patient collection
4) genotype driven phenotyping
5) genetic risk prediction
6) biological follow-up of candidate genes
7) generation and study of pathways and biology in induced pluripotent stem cells from patients.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Sklar during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.